Effects of ozanimod on myelin dynamics and neurodegeneration in patients with relapsingremitting multiple sclerosis: correlation with disease activity, cognition, fatigue,depression and quality of life

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513960-24-00

Enrollment

Registered

2024-07-01

Start date

2022-06-22

Completion date

Unknown

Last updated

2024-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis patients in relapse and remission form

Brief summary

The primary endpoints of this study are to assess, in RRMS patients treated with ozanimod, the changes from baseline over 2 years of: • Global brain atrophy (i.e., percent brain volume change [PBVC]); • Regional GM volume; • Regional WM volume; • Thalamic volume; • Cortical volume.

Interventions

DRUG-

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The primary endpoints of this study are to assess, in RRMS patients treated with ozanimod, the changes from baseline over 2 years of: • Global brain atrophy (i.e., percent brain volume change [PBVC]); • Regional GM volume; • Regional WM volume; • Thalamic volume; • Cortical volume.	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026